Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib have?
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib has 17 citations in the OpenAlex counts ScholarIQ stores.
When was Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib published?
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib has 2015 year in the ScholarIQ index.
What is the open-access status of Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib?
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib has gold oa status in the ScholarIQ index.
What is the DOI of Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib?
The DOI for Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib is on the source record.
What is the PMID of Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib?
The PMID for Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib is on the source record.
What is the OpenAlex record for Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib?
The OpenAlex for Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib is on the source record.